$DRMA
Dermata Therapeutics Inc

2024 Q3 Form 10-Q Financial Statement

#000165495424010103 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $874.6K
YoY Change -2.11%
% of Gross Profit
Research & Development $2.009M
YoY Change 139.48%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.884M
YoY Change 66.46%
Operating Profit -$2.884M
YoY Change 66.46%
Interest Expense $54.64K
YoY Change 75.97%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.829M
YoY Change 66.29%
Income Tax
% Of Pretax Income
Net Earnings -$2.829M
YoY Change 66.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.18
COMMON SHARES
Basic Shares Outstanding 1.316M shares 6.661M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.947M
YoY Change -41.37%
Cash & Equivalents $4.947M
Short-Term Investments
Other Short-Term Assets $289.5K
YoY Change 5.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.237M
YoY Change -39.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.00
YoY Change 100.0%
TOTAL ASSETS
Total Short-Term Assets $5.237M
Total Long-Term Assets $2.00
Total Assets $5.237M
YoY Change -39.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.327M
YoY Change 203.16%
Accrued Expenses $591.3K
YoY Change 141.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.918M
YoY Change 180.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.918M
Total Long-Term Liabilities $0.00
Total Liabilities $1.918M
YoY Change 180.94%
SHAREHOLDERS EQUITY
Retained Earnings -$59.35M
YoY Change 19.82%
Common Stock $69.00
YoY Change -78.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.318M
YoY Change
Total Liabilities & Shareholders Equity $5.237M
YoY Change -39.9%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.829M
YoY Change 66.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.126M
YoY Change 15.52%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.339M
YoY Change 54.71%
NET CHANGE
Cash From Operating Activities -2.126M
Cash From Investing Activities
Cash From Financing Activities 2.339M
Net Change In Cash 213.5K
YoY Change -165.03%
FREE CASH FLOW
Cash From Operating Activities -$2.126M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
693175 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
261998 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company is exposed to credit risk in the event of a default by the financial institutions holding the Company’s cash and cash equivalents to the extent of the amounts held in excess of FDIC limits. The Company limits its credit risk by placing its cash and cash equivalents with financial institutions it believes are of high quality. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
dei Entity Central Index Key
EntityCentralIndexKey
0001853816
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
693175 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
261998 shares
drma Incremental Fair Value Of March2023 Warrant Modification
IncrementalFairValueOfMarch2023WarrantModification
144765 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40739
dei Entity Registrant Name
EntityRegistrantName
DERMATA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3218736
dei Entity Address Address Line1
EntityAddressAddressLine1
3525 Del Mar Heights Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
#322
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
800-2543
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1315981 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4947100 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
289452 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
540499 usd
CY2024Q2 us-gaap Assets
Assets
5236552 usd
CY2023Q4 us-gaap Assets
Assets
7978634 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1327179 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
866028 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
591246 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
757588 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1918425 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1623616 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
69 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
26 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62669304 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59742870 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59351246 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53387878 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3318127 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5236552 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7978634 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2009102 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
838931 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3609843 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2031564 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
874640 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
893483 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2477459 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1978532 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2883742 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1732414 usd
us-gaap Operating Expenses
OperatingExpenses
6087302 usd
us-gaap Operating Expenses
OperatingExpenses
4010096 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2883742 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1732414 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6087302 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4010096 usd
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
54636 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
31050 usd
us-gaap Interest Income Other
InterestIncomeOther
123934 usd
us-gaap Interest Income Other
InterestIncomeOther
68590 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2829106 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
us-gaap Net Income Loss
NetIncomeLoss
-5963368 usd
us-gaap Net Income Loss
NetIncomeLoss
-3941506 usd
CY2024Q2 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-4.18
CY2023Q2 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-9.43
drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-10.64
drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-31.96
CY2024Q2 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
676567 shares
CY2023Q2 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
180332 shares
drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
560282 shares
drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
123344 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587234 usd
CY2024Q1 drma Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3134262 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3807990 usd
CY2024Q2 drma Issuance Of Common Stock Upon Exercise Of Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockUponExerciseOfWarrantsNetOfIssuanceCostsAmount
2320463 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19608 usd
CY2024Q2 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-828 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2829106 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3318127 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131260 usd
CY2023Q1 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4174985 usd
CY2023Q1 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
153 usd
CY2023Q1 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-40 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8088070 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
1512102 usd
CY2023Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
34 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8030019 usd
us-gaap Profit Loss
ProfitLoss
-5963368 usd
us-gaap Profit Loss
ProfitLoss
-3941506 usd
us-gaap Share Based Compensation
ShareBasedCompensation
606842 usd
us-gaap Share Based Compensation
ShareBasedCompensation
262437 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
367802 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
428843 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
360253 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58924 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-201936 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-180848 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1132961 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
451508 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4830407 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3489998 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2410200 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5687087 usd
us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
70000 usd
us-gaap Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
187 usd
drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
-828 usd
drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
-40 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2339372 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5687234 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2491035 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2197236 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6241294 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4947100 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8438530 usd
drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
-18 usd
drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
0 usd
drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
1526232 usd
drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
0 usd
drma Equity Issuance Costs In Accounts Payable Or Accrued Expenses
EquityIssuanceCostsInAccountsPayableOrAccruedExpenses
89737 usd
drma Equity Issuance Costs In Accounts Payable Or Accrued Expenses
EquityIssuanceCostsInAccountsPayableOrAccruedExpenses
0 usd
drma Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
46755 usd
drma Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
950 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
950 usd
CY2024Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
4900000 usd
CY2024Q2 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
-59400000 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
4800000 usd
CY2023 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
6400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
100000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1137046 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
296853 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
42.30
CY2023Q4 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
9.7665
drma Description Of Abeyance Shares
DescriptionOfAbeyanceShares
the Holder left 182,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request, which were then delivered to the Holder on January 8, 2024
CY2023Q4 drma Temporary Equity Shares Abeyance
TemporaryEquitySharesAbeyance
182000 shares
CY2023Q2 drma Proceeds Cash From Pipe
ProceedsCashFromPipe
1500000 usd
CY2023Q2 drma Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
300000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1109705 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
772973 shares
CY2024Q2 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
5.16
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.91
CY2023Q4 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
5.16
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.7655
CY2023Q4 drma Received Net Cash Proceeds
ReceivedNetCashProceeds
2000000.0 usd
CY2023Q4 drma Offering Expenses
OfferingExpenses
3000000.0 usd
drma Warrant Reduced Description
WarrantReducedDescription
from $318.00 to $42.30 per share upon closing of the March 2023 Offering
CY2024Q1 drma Description Of Stock Option Cancellation
DescriptionOfStockOptionCancellation
in accordance with an option cancellation agreement. Accordingly, 6,747 of the 6,763 stock options outstanding as of December 31, 2023, were cancelled in February 2024
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
568372 usd
CY2024Q2 drma Common Stock Par Or Stated Values Per Share
CommonStockParOrStatedValuesPerShare
2.39
us-gaap Contractually Specified Servicing Fees Amount
ContractuallySpecifiedServicingFeesAmount
6900000 usd
us-gaap Other Expenses
OtherExpenses
2900000 usd
CY2024Q2 us-gaap General Partners Offering Costs
GeneralPartnersOfferingCosts
1157761 usd

Files In Submission

Name View Source Status
0001654954-24-010103-index-headers.html Edgar Link pending
0001654954-24-010103-index.html Edgar Link pending
0001654954-24-010103.txt Edgar Link pending
0001654954-24-010103-xbrl.zip Edgar Link pending
drma-20240630.xsd Edgar Link pending
drma_10q.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
drma-20240630_cal.xml Edgar Link unprocessable
drma-20240630_def.xml Edgar Link unprocessable
drma-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drma_10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drma-20240630_lab.xml Edgar Link unprocessable